Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00184366
Status:
TERMINATED
Last Update Posted:
2012-01-19
First Post:
2005-09-13
Brief Title:
Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis
Sponsor:
Norwegian University of Science and Technology
Organization:
Norwegian University of Science and Technology
Study Overview
Official Title:
Classification and Characterization of Patients Suffering From Moderate to Severe Plaque Psoriasis Responding to Subcutaneous Administered Efalizumab
Status:
TERMINATED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
efalizumab was withdrawn from market full 2 years follow-up only 14 patients
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objectives of the project are
To classify patients suffering from plaque psoriasis responding on a given treatment efalizumab based upon reduction in Psoriasis Area and severity Index PASI Psoriasis Disability Index 8PDI and dermatology Life Quality Index 8 DLQI
To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab
To classify patients suffering from plaque psoriasis responding on a given treatment efalizumab based upon reduction in Psoriasis Area and severity Index PASI Psoriasis Disability Index 8PDI and dermatology Life Quality Index 8 DLQI
To characterize patients suffering from plaque psoriasis responding to or not responding to subcutaneous administrated efalizumab
Detailed Description:
This is an investigator initiatedprospective longitudinal observation study Before starting treatment with efalizumab we will record factors such as demographic data type of psoriasis previous treatment other diseases etc
We will follow the patients and classify them as responders and non-responders We hope to find 4-5 factors which we can use later to predict response of this drug
We will follow the patients and classify them as responders and non-responders We hope to find 4-5 factors which we can use later to predict response of this drug
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None